Sector: Pharmaceuticals & Biotechnology

Mid Cap

Natco Pharma Share Price

Natco Pharma Ltd.

₹886

-5.70(-0.64%)

Invest in NATCOPHARM with up to 2.22x margin.

Trade with MTF

23rd Feb 2026 | 3:28 PM

NSE : NATCOPHARM

Open Free Demat Account

Natco Pharma Performance

Price Movement

₹886.00

₹885.55

₹906.40

↘ Today's Low↗ Today's High

1 Year Performance

₹886.00

₹726.80

₹1059.00

↘ 52 Week Low↗ 52 Week High

Markets Today

High₹906.40

Low₹885.55

Open at₹895.00

Prev Close₹891.70

Volumes3.84 L

Avg Price₹892.74

Lower Circuit₹713.40

Upper Circuit₹1,070.00

Historical Performance

3M High₹960.40

3M Low₹806.05

1 Yr High₹1,059.00

1 Yr Low₹726.80

3 Yr High₹1,639.00

3 Yr Low₹520.25

5 Yr High₹1,639.00

5 Yr Low₹502.00

Natco Pharma Fundamentals

Market Cap

High in industry

15,994.50 Cr.

PE Ratio (TTM)

Below industry Median

10.30

Dividend Yield

Above industry Median

0.60

Net Profit TTM

17% decr over last year

1,557.20

Net Profit Growth

17% decr over last year

1,557.20

PEG Ratio

Negative PEG TTM

-0.60

ROE

4.5% incr over last year

24.78

Operating Revenue TTM

4,560.20

Operating Revenue Growth

6.6% incr over last year

Book Value

Below industry Median

1.80

MFI

MFI strongly Overbought

85.46

RSI

RSI is mid-range

59.20

EPS (TTM)

105.26

Debt to Equity

0.04

Face Value

Operating Profit Margin Qtr.

45.90

Operating Profit Qtr.

158.70

Net Profit Qtr.

151.50

Operating Revenue Qtr.

647.30

PB Ratio

1.80

Natco Pharma Financials

*All values are in Rs. Cr

Loading chart...

Indicator	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024
Total Revenue	528.80	1,264.30	1,192.70	1,157.40	407.60
Operating Expense	408.50	711.80	653	596.20	378.20
Operating Profit	120.30	552.50	539.70	561.20	29.40
Depreciation	42.10	48.10	53.80	93.70	43.70
Interest	8.30	11.70	2.60	8.80	3.40
Tax	18.30	85.10	78.80	92.70	25.40
Net Profit	106.90	500.90	464.10	428.10	124.90

Natco Pharma Technicals

Natco Pharma Ltd. EMA & SMA

₹886.00

-5.70 (-0.64%)

↗ Bullish Moving Average

↘ Bearish Moving Average

Day EMA5 ₹882.1

Day EMA10 ₹869.4

Day EMA12 ₹866.2

Day EMA20 ₹860.5

Day EMA26 ₹860

Day EMA50 ₹862.9

Day EMA100 ₹869

Day EMA200 ₹900.1

Natco Pharma Support and Resistance

Resistance

First Resistance₹898.40

Second Resistance₹905.10

Third Resistance₹915.30

Support

First Support₹881.50

Second Support₹871.30

Third Support₹864.60

Technical Indicators

Day RSI59.20

Day MFI85.46

Day ADX20.21

Day Commodity Channel Index123.20

William-33.67

Day MACD6.14

Day MACD Signal Line-2.49

Day ATR31.55

Day ROC1251.19

Day ROC216.82

Natco Pharma Shareholding Pattern

Held By	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Promoter	49.6	49.6	49.6	49.6	49.5	49.5
FII	17.5	17.9	17.5	15.5	14.1	15.2
DII	6.8	5.6	5.6	5.8	5.9	5.4
Public	26.1	26.9	27.3	29.1	30.6	30

Natco Pharma Delivery And Volume

Period	Combined Delivery Volume	NSE+BSE Traded Volume Avg	Daily Avg Delivery Volume %
Day	1.62 L	5.02 L	32.28%
Week	8.48 L	62.65 L	13.54%
1 Month	3.71 L	18.47 L	20.06%
6 Month	3.26 L	13.03 L	25.00%

Natco Pharma SWOT Analysis

Strengths24

Weakness3

Opportunity1

Threats2

Companies with current TTM PE Ratio less than 3 Year, 5 Year and 10 Year PE

Buy Zone: Stocks in the buy zone based on days traded at current PE and P/BV

Strong Momentum: Price above short, medium and long term moving averages

Mid-range Performer (DVM)

Relative Outperformance versus Industry over 1 Month

Rising Net Cash Flow and Cash from Operating activity

Relative Outperformance versus Industry over 1 Year

Companies that saw improvement in net profits, operating profit margin and revenues in the most recent quarter

PEG lower than Industry PEG

High Momentum Scores (Technical Scores greater than 50)

Relative Outperformance versus Industry over 1 Week

Relative Outperformance versus Industry over 1 Month

Overbought by Money Flow Index (MFI)

Effectively using its capital to generate profit - RoCE improving in last 2 years

Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year

Efficient in managing Assets to generate Profits - ROA improving since last 2 year

Companies with Low Debt

Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years

Annual Net Profits improving for last 2 years

Book Value per share Improving for last 2 years

Companies with Zero Promoter Pledge

RSI indicating price strength

Top Gainers

Stocks Outperforming their Industry Price Change in the Quarter

Natco Pharma Corporate Action

Ex-Date	Dividend Amount	Dividend Type	Record Date	Instrument Type
18 Feb, 2026	1.5	INTERIM	18 Feb, 2026	Equity Share
20 Nov, 2025	1.5	INTERIM	20 Nov, 2025	Equity Share
19 Aug, 2025	2	INTERIM	19 Aug, 2025	Equity Share
18 Feb, 2025	1.5	INTERIM	18 Feb, 2025	Equity Share
27 Nov, 2024	1.5	INTERIM	27 Nov, 2024	Equity Share
23 Aug, 2024	3	INTERIM	23 Aug, 2024	Equity Share
26 Feb, 2024	1.25	INTERIM	26 Feb, 2024	Equity Share
24 Nov, 2023	1.25	INTERIM	24 Nov, 2023	Equity Share
22 Aug, 2023	7	INTERIM	22 Aug, 2023	Equity Share
21 Feb, 2023	1.25	INTERIM	21 Feb, 2023	Equity Share

Natco Pharma Stock Comparison

Financials	Corona Remedies Ltd.	Sudeep Pharma Ltd.	Rubicon Research Ltd.	Sai Life Science Ltd.	OneSource Specialty Pharma Ltd.	Sanofi Consumer Healthcare India Ltd.
Price (₹)	₹1,577	₹628.95	₹780	₹968	₹1,320	₹4,075
% Change	3.47%	-5.40%	-0.01%	2.83%	3.96%	0.75%
Revenue TTM (₹ Cr)	-	-	₹1,598.19	₹2,169.86	₹1,419.33	₹798.10
Net Profit TTM (₹ Cr)	-	-	₹206.20	₹332.94	₹20.10	₹217.90
PE TTM	-	-	62.20	61.50	754.90	43.10
1 Year Return	48.29	6.51	60.63	37.17	3.9	-12.48
ROCE	30.24	34.78	34.76	12.51	3.26	-

Similar Stocks

AKUMS

Akums Drugs & Pharmaceuticals Ltd.

₹ 474.00

-0.91%

BLUEJET

Blue Jet Healthcare Ltd

₹ 391.40

+9.99%

CONCORDBIO

Concord Biotech Ltd.

₹ 1103.00

+0.46%

AARTIPHARM

Aarti Pharmalabs Ltd.

₹ 687.60

-1.60%

SUPRIYA

Supriya Lifescience Ltd.

₹ 670.00

-1.17%

ACUTAAS

Acutaas Chemicals Ltd.

₹ 2138.50

+1.52%

ALIVUS

Alivus Life Sciences Ltd.

₹ 901.15

-1.08%

COHANCE

Cohance Lifesciences Ltd.

₹ 315.10

+3.18%

ERIS

Eris Lifesciences Ltd.

₹ 1358.00

+1.16%

SYNGENE

Syngene International Ltd.

₹ 448.60

+1.33%

APLLTD

Alembic Pharmaceuticals Ltd.

₹ 774.90

+1.55%

STAR

Strides Pharma Science Ltd.

₹ 872.90

+0.37%

GRANULES

Granules India Ltd.

₹ 598.00

-0.18%

FDC

FDC Ltd.

₹ 383.00

+3.82%

SHILPAMED

Shilpa Medicare Ltd.

₹ 329.00

+1.29%

JUBLPHARMA

Jubilant Pharmova Ltd.

₹ 900.00

+3.15%

CAPLIPOINT

Caplin Point Laboratories Ltd.

₹ 1739.00

+2.77%

NEULANDLAB

Neuland Laboratories Ltd.

₹ 13507.00

+6.88%

MARKSANS

Marksans Pharma Ltd.

₹ 179.32

+0.53%

SANOFI

Sanofi India Ltd.

₹ 4080.00

+1.34%

PGHL

Procter & Gamble Health Ltd.

₹ 5080.00

+1.21%

JSLL

Jeena Sikho Lifecare Ltd.

₹ 674.90

-2.16%

FAQ's on NATCOPHARM

What is the current share price of Natco Pharma Ltd.?

As of 6 June 2025 at 10:01 AM, the share price for Natco Pharma Ltd. is ₹ 886 on the NSE and ₹ 887 on the BSE. (Note: Prices are dynamic and update frequently during market hours).

What is the Market Capitalization of Natco Pharma Ltd.?

Market capitalization (market cap) represents the total market value of a company's outstanding shares based on its current share price. As of 6 June 2025, the market cap for Natco Pharma Ltd. is approximately ₹ 15994.5 Cr.

What are the PE and PB ratios for Natco Pharma Ltd.?

Based on recent data, the Price-to-Earnings (PE) ratio for Natco Pharma Ltd. is 10.3, and the Price-to-Book (PB) ratio is 1.8.

What is the 52-Week High and Low for Natco Pharma Ltd.?

Over the past 52 weeks, the highest price reached by Natco Pharma Ltd. shares was ₹ 1059, and the lowest price was ₹ 726.8.

What is the current dividend yield for Natco Pharma Ltd.?

As of 6 June 2025, the dividend yield for Natco Pharma Ltd. is 0.6%. The dividend yield is calculated based on the company's annual dividend payouts relative to its current share price.

Who are the major shareholders of Natco Pharma Ltd.?

Significant shareholdings in Natco Pharma Ltd. typically include entities such as:

Promoter
Public
FII
Other Institutions
Mutual Funds

(Note: Shareholding patterns can change; this represents major holders based on recent filings).

Who are the peers of Natco Pharma Ltd. in the Pharmaceuticals & Biotechnology sector?

In the Pharmaceuticals & Biotechnology sector, Natco Pharma Ltd. is often compared with other major players such as Accretion Nutraveda, Rekvina Laboratories, Vivimed Labs, Corona Remedies, Sudeep Pharma and Curis Lifesciences for analysis and benchmarking.

What is the latest dividend information for Natco Pharma Ltd.?

Natco Pharma Ltd. last declared a INTERIM dividend of ₹ 1.5 per share for the financial period ending 2026. The record date was set as 2026-02-18, and the payment was/is scheduled around 2026-02-18. For the most current dividend announcements, refer to official company filings.

Invest Anytime, Anywhere

By signing up I certify terms, conditions & privacy policy